GRI Bio, Inc.

GRI Bio shows no cyber incidents or red-flag 8-K filings in our 90-day monitoring window. However, absence of recent events does not indicate absence of risk; a biotech company's underlying exposure depends heavily on capital structure, dilution trajectory, and financing dependency. The full $49 Report extends analysis to twelve months of filing history, calculates dilution risk scores, maps the complete 8-K timeline, and surfaces AI-detected financing stress signals. The full $49 Report adds quantified dilution risk, 12-month event context, and early-warning financing indicators.